These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and Wang L; Song J; Xiao X; Li D; Liu T; He X J Chemother; 2024 May; 36(3):202-207. PubMed ID: 37599456 [TBL] [Abstract][Full Text] [Related]
3. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience]. Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674 [No Abstract] [Full Text] [Related]
4. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study. Pasvolsky O; Shimony S; Ram R; Shimoni A; Shargian L; Avni B; Wolach O; Shochat T; Yerushalmi R; Amit O; Raanani P; Yeshurun M Ann Hematol; 2022 Feb; 101(2):379-387. PubMed ID: 34628534 [TBL] [Abstract][Full Text] [Related]
5. Impact of the Addition of Antithymocyte Globulin to Post-Transplantation Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood Compared to Post-Transplantation Cyclophosphamide Alone in Acute Myelogenous Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Battipaglia G; Labopin M; Blaise D; Diez-Martin JL; Bazarbachi A; Vitek A; Chevallier P; Castagna L; Grillo G; Daguindau E; López-Jiménez J; Koc Y; Ruggeri A; Nagler A; Mohty M Transplant Cell Ther; 2022 Sep; 28(9):587.e1-587.e7. PubMed ID: 35714906 [TBL] [Abstract][Full Text] [Related]
6. [Venetoclax and azacitidine induced cytogenetic response in an elderly patient with IDH2- and DNMT3A-mutated refractory acute myeloid leukemia]. Kunisada K; Matsuoka A; Yoshida S; Taoka T Rinsho Ketsueki; 2022; 63(12):1621-1625. PubMed ID: 36653133 [TBL] [Abstract][Full Text] [Related]
7. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia. Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Venugopal S; Takahashi K; Daver N; Maiti A; Borthakur G; Loghavi S; Short NJ; Ohanian M; Masarova L; Issa G; Wang X; Carlos BR; Yilmaz M; Kadia T; Andreeff M; Ravandi F; Konopleva M; Kantarjian HM; DiNardo CD Blood Cancer J; 2022 Jan; 12(1):10. PubMed ID: 35078972 [TBL] [Abstract][Full Text] [Related]
9. [Efficacy of Venetoclax Plus Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia Patients with Weng GY; You WW; Liu HX; Cai Y; DU X Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1333-1339. PubMed ID: 37846681 [TBL] [Abstract][Full Text] [Related]
10. Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms. Carter JL; Su Y; Qiao X; Zhao J; Wang G; Howard M; Edwards H; Bao X; Li J; Hüttemann M; Yang J; Taub JW; Ge Y Biochem Pharmacol; 2023 Oct; 216():115759. PubMed ID: 37604291 [TBL] [Abstract][Full Text] [Related]
11. Outcomes of haploidentical peripheral stem cell transplantation with combination of post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) compared to unrelated donor transplantation in acute myeloid leukemia: A retrospective 10-year experience. Barkhordar M; Kasaeian A; Janbabai G; Mousavi SA; Fumani HK; Tavakoli S; Bahri T; Ghavamzadeh A; Vaezi M Leuk Res; 2022 Sep; 120():106918. PubMed ID: 35843087 [TBL] [Abstract][Full Text] [Related]
12. Effect of Graft-versus-Host Disease on Post-Transplantation Outcomes following Single Cord Blood Transplantation Compared with Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Adult Acute Myeloid Leukemia. Konuma T; Matsuda K; Shimomura Y; Tanoue S; Sugita J; Inamoto Y; Hirayama M; Ara T; Nakamae H; Ota S; Maruyama Y; Eto T; Uchida N; Tanaka M; Ishiwata K; Koi S; Takahashi S; Ozawa Y; Onizuka M; Kanda Y; Kimura T; Ichinohe T; Atsuta Y; Kanda J; Yanada M Transplant Cell Ther; 2023 Jun; 29(6):365.e1-365.e11. PubMed ID: 36889507 [TBL] [Abstract][Full Text] [Related]
13. Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy. Winters AC; Bosma G; Abbott D; Minhajuddin M; Jordan C; Pollyea DA; Gutman JA Transplant Cell Ther; 2022 Oct; 28(10):694.e1-694.e9. PubMed ID: 35902048 [TBL] [Abstract][Full Text] [Related]
14. Venetoclax Plus Azacitidine as a Bridge Treatment to Allogeneic Stem Cell Transplantation in Unfit Patients with Acute Myeloid Leukemia. Chen TT; Lin CC; Lo WJ; Hsieh CY; Lein MY; Lin CH; Lin CY; Bai LY; Chiu CF; Yeh SP Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539418 [TBL] [Abstract][Full Text] [Related]
15. Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome. Slade M; DiPersio JF; Westervelt P; Vij R; Schroeder MA; Romee R Biol Blood Marrow Transplant; 2017 Oct; 23(10):1736-1743. PubMed ID: 28688919 [TBL] [Abstract][Full Text] [Related]
16. Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective study. Pelland AA; Deschênes-Simard X; Savard X; Giguère P; Spillane D; Barabé F; Laroche V; Munger M; Gallagher G; Marcoux N; Cantin G; Chénard-Poirier M; Delage R; Lalancette M; Veilleux O; Assouline SE; Lemieux C Leuk Lymphoma; 2024 Dec; 65(13):1974-1982. PubMed ID: 39129334 [TBL] [Abstract][Full Text] [Related]
17. Modified combination of anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) as compared with standard ATG protocol in haploidentical peripheral blood stem cell transplantation for acute leukemia. Barkhordar M; Kasaeian A; Janbabai G; Kamranzadeh Fumani H; Tavakoli S; Rashidi AA; Mousavi SA; Ghavamzadeh A; Vaezi M Front Immunol; 2022; 13():921293. PubMed ID: 35990618 [TBL] [Abstract][Full Text] [Related]
18. Sequential Combination of FLAM and Venetoclax plus Azacitidine to Bridge to Cord Blood Transplantation in a Patient with Primary Induction Failure Acute Myeloid Leukemia. Murakami H; Matsuoka KI; Asano T; Moriyama T; Matsumura A; Fujiwara H; Asada N; Ennishi D; Nishimori H; Fujii K; Fujii N; Toji T; Yoshino T; Maeda Y Case Rep Oncol; 2022; 15(3):974-979. PubMed ID: 36636684 [TBL] [Abstract][Full Text] [Related]
19. Successful combination treatment with azacitidine and venetoclax as a bridging therapy for third allogenic stem cell transplantation in a patient with 11q23/MLL-rearranged complex karyotype acute myeloid leukemia. Edahiro T; Ureshino H; Chishaki R; Fujino K; Mino T; Yoshida T; Fukushima N; Ichinohe T EJHaem; 2023 Feb; 4(1):273-275. PubMed ID: 36819153 [TBL] [Abstract][Full Text] [Related]
20. Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia. Nagler A; Labopin M; Dholaria B; Angelucci E; Afanasyev B; Cornelissen JJ; Sica S; Meijer E; Ciceri F; Van Gorkom G; Kröger N; Martin H; Pioltelli P; Risitano A; Canaani J; Savani BN; Sanz J; Mohty M Clin Cancer Res; 2021 Feb; 27(3):843-851. PubMed ID: 33148668 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]